221 related articles for article (PubMed ID: 16738903)
21. Psoriasis, erythema nodosum, and nummular eczema onset in an ankylosing spondylitis patient treated with infliximab.
Delle Sedie A; Bazzichi L; Bombardieri S; Riente L
Scand J Rheumatol; 2007; 36(5):403-4. PubMed ID: 17963173
[No Abstract] [Full Text] [Related]
22. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
Suwannalai P; Auethavekiat P; Udomsubpayakul U; Janvitayanujit S
Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
[TBL] [Abstract][Full Text] [Related]
23. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.
Jha A; Upton A; Dunlop WC; Akehurst R
Adv Ther; 2015 Aug; 32(8):742-56. PubMed ID: 26343027
[TBL] [Abstract][Full Text] [Related]
24. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
25. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Sieper J; Emery P; Keystone EC; Schiff MH; Mease P; van Riel PL; Fleischmann R; Weisman MH; Weinblatt ME
Ann Rheum Dis; 2007 Nov; 66 Suppl 3(Suppl 3):iii2-22. PubMed ID: 17934088
[No Abstract] [Full Text] [Related]
26. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial.
Antoni C; Krueger GG; de Vlam K; Birbara C; Beutler A; Guzzo C; Zhou B; Dooley LT; Kavanaugh A;
Ann Rheum Dis; 2005 Aug; 64(8):1150-7. PubMed ID: 15677701
[TBL] [Abstract][Full Text] [Related]
27. Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment.
Nikas SN; Voulgari PV; Takalou IP; Katsimbri P; Drosos AA
Ann Rheum Dis; 2005 Nov; 64(11):1665-7. PubMed ID: 16227426
[No Abstract] [Full Text] [Related]
28. Golimumab: in the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Oldfield V; Plosker GL
BioDrugs; 2009; 23(2):125-35. PubMed ID: 19489653
[TBL] [Abstract][Full Text] [Related]
29. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
[TBL] [Abstract][Full Text] [Related]
30. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
31. Tuberculosis following therapy with infliximab may be refractory to antibiotic therapy.
Taylor JC; Orkin R; Lanham J
Rheumatology (Oxford); 2003 Jul; 42(7):901-2. PubMed ID: 12826707
[No Abstract] [Full Text] [Related]
32. Infliximab in psoriasis and psoriatic arthritis.
Papoutsaki M; Osório F; Morais P; Torres T; Magina S; Chimenti S; Costanzo A
BioDrugs; 2013 Jan; 27 Suppl 1():13-23. PubMed ID: 23990278
[TBL] [Abstract][Full Text] [Related]
33. [A case of generalized tuberculosis in the use of infliximab (Remicade) in patients with Bekhterev's disease].
Nekrasov EV; Strelis AK; Ianova GV; Filiniuk OV; Buĭnova LN
Tuberk Biolezni Legkih; 2009; (8):56-60. PubMed ID: 19803353
[No Abstract] [Full Text] [Related]
34. Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up.
Kurizky PS; Galvão LO; Martins GA
An Bras Dermatol; 2019; 94(4):483-484. PubMed ID: 31644629
[No Abstract] [Full Text] [Related]
35. Alopecia areata universalis elicited during treatment with adalimumab.
Pelivani N; Hassan AS; Braathen LR; Hunger RE; Yawalkar N
Dermatology; 2008; 216(4):320-3. PubMed ID: 18230980
[TBL] [Abstract][Full Text] [Related]
36. Clinical inquiries. Are DMARDs effective for rheumatologic diseases besides rheumatoid arthritis?
Goodemote P; Jamieson B; Hoffman R
J Fam Pract; 2007 Nov; 56(11):933-4, 937. PubMed ID: 17976342
[No Abstract] [Full Text] [Related]
37. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
38. Sézary syndrome in a patient receiving infliximab for ankylosing spondylitis.
Dauendorffer JN; Rivet J; Allard A; Bachelez H
Br J Dermatol; 2007 Apr; 156(4):742-3. PubMed ID: 17263820
[TBL] [Abstract][Full Text] [Related]
39. Infliximab-induced lupus-like syndrome in a patient with ankylosing spondylitis.
Bodur H; Eser F; Konca S; Arikan S
Rheumatol Int; 2009 Feb; 29(4):451-4. PubMed ID: 18712523
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
